Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Rhea-AI Summary
Sunshine Biopharma (NASDAQ:SBFM) approved a 1-for-10 reverse stock split of its common shares, effective at market open on June 1, 2026. The action aims to regain compliance with Nasdaq’s minimum bid price requirement and will reduce outstanding shares from 21,236,346 to approximately 2,123,635.
Positive
- Reverse split targets Nasdaq minimum bid price compliance
- Outstanding shares reduced from 21,236,346 to about 2,123,635
Negative
- Reverse stock split may signal prior share price weakness
- Share consolidation can be viewed as unfavorable by some investors
News Market Reaction – SBFM
In the May 28 session, SBFM declined 25.31%, reflecting a significant negative market reaction. Argus tracked a trough of -41.0% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Stock split Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Reverse stock split | Positive | -22.8% | 1-for-20 reverse split to regain Nasdaq minimum bid compliance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior reverse split on Aug 6, 2024 framed as a compliance step was followed by a -22.84% move, showing past pressure around similar actions.
The company has used reverse splits before to address Nasdaq bid-price compliance. On Aug 6, 2024, Sunshine Biopharma announced a 1-for-20 reverse split aimed at maintaining its Nasdaq listing. That event preceded a -22.84% 24-hour price reaction. Today’s 1-for-10 reverse split again targets bid-price compliance, fitting into a pattern of using capital actions alongside its broader pharmaceutical strategy to retain exchange status.
Key Terms
reverse stock split financial
minimum bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 21,236,346 to approximately 2,123,635.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire